甲基强的松龙联合静注人免疫球蛋白治疗小儿重症手足口病的疗效观察
Curative Effect Observation between Different Dose of Methylprednisolone with the Human Immunoglobulin in the Treatment of Children with Severe Hand Foot and Mouth Disease
摘要:
目的:观察不同剂量甲基强的松龙联合丙种免疫球蛋白治疗小儿重症手足口病的临床疗效。方法:研究对象选取100例重症手足口病患儿,根据甲基强的松龙治疗剂量不同,分为大剂量组、小剂量组各50例,对比两组疗效。结果显示两组在总有效率、神经受累时间及住院时间方面并无显著差异(P > 0.05)。但小剂量组在退热时间上明显低于大剂量组(P < 0.05);结论:甲基强的松龙联合丙种球蛋白治疗重症手足口病的疗效确切,应用不同剂量甲基强的松龙对于神经受累改善及住院时间影响上并无显著差异,但小剂量应用甲基强的松龙则能够有效缩短患儿的发热时间,该治疗方法值得推广。
Abstract:
Objective: To compare the clinical efficacy of different doses of methylprednisolone with the human immunoglobulin in the treatment of severe hand foot mouth disease in children. Methods: We selected 100 cases of children with severe hand foot mouth disease, and divided them into large dose group and small dose group with 50 cases in each group on the basis of methylprednisolone usage, both groups were given the human immunoglobulin treatments. Curative effects were compared between the two groups. Results: The neurological involvement time and hospital stays between the two groups were not significant (P > 0.05), but the low dose group was significantly lower than that of high dose group in the febrile time (P < 0.05). Conclusion: Glucocorticoid with the human immunoglobulin in the treatment of severe hand foot mouth disease has definite ther-apeutic effect, but there is no statistic difference in the hospital stays and neurological involvement between the two groups, however, application of small dose of methylprednisolone can effectively shorten the febrile time, which was worthing of clinical promotion and application.
参考文献
|
[1]
|
王会亮, 张玉睿, 武平, 等. 不同剂量甲泼尼龙治疗重症手足口病疗效观察[J]. 医学综述, 2012, 18(20): 3497-3498.
|
|
[2]
|
孙广超, 杨思达, 陶建平, 等. 重症和危重症手足口病患儿外周血T淋巴细胞亚群分析[J]. 中国循证儿科杂志, 2010, 5(4): 251-254.
|
|
[3]
|
李玉萍, 马娜. 不同剂量甲基强的松龙治疗重症手足口病疗效观察[J]. 中华实用诊断与治疗杂志, 2009, 24(4): 389-390.
|
|
[4]
|
田庆玲, 庞保东, 张双, 等. 不同剂量甲泼尼龙治疗重症手足口病疗效比较[J]. 中国妇幼保健, 2012, 27(10): 1564-1566.
|
|
[5]
|
蒋太敏. 不同剂量甲泼尼龙治疗重症手足口病比较分析[J]. 中外医学研究, 2015, 13(5): 28-30.
|
|
[6]
|
Mc-Mina, P.C. (2007) An Overview of the Evolution of En-terovirus 71 and Its Clinical and Public Health Significant. FEMS Microbiology Reviews, 26, 91-107. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
毛月燕, 姚建华. 重症手足口病早期诊断与治疗及其预后[J]. 中华传染病杂志, 2009, 27(1): 35-38.
|
|
[8]
|
黎念, 雷伟. 手足口病研究进展[J]. 重庆医学, 2011, 40(1): 93-95.
|
|
[9]
|
熊燕. 早期静注人免疫球蛋白治疗重症手足口病的临床研究[J]. 中国现代医生, 2012, 50(8): 134-135.
|
|
[10]
|
叶科军. 丙种球蛋白治疗小儿重症手足口病疗效观察[J]. 吉林医学, 2013, 34(32): 6733-6734.
|
|
[11]
|
崔永忠. 静脉注射不同剂量丙种球蛋白治疗重症手足口病的疗效观察[J]. 中国实用医药, 2011, 6(25): 152-153.
|
|
[12]
|
Chang, L.Y., Lin, T.Y., Hsu, K.H., et al. (1999) Clinical Features and Risk Factors of Pulmonary Oe-dema after Enterovirus-71-Related Hand, Foot, and Mouth Disease. Lancet, 354, 1682-1686. [Google Scholar] [CrossRef]
|